胸腺肽α1缓解EGFR-TKI对EGFR敏感突变NSCLC患者T淋巴细胞亚群抑制的研究

Thymosin α1 was able to relieve the inhibitory effect of EGFR-TKI on peripheral blood T lymphocyte subsets of the patients with non-small cell lung cancer

目的探讨表皮生长因子受体(EGFR)敏感突变非小细胞肺癌(NSCLC)患者接受EGFR-TKI单药,以及EGFR-TKI联合胸腺肽α1治疗前后外周血T淋巴细胞亚群的变化。方法采集我院2008年5月至2018年8月期间接受单药EGFR-TKI和EGFR-TKI联合胸腺肽α1治疗的NSCLC患者的外周血T淋巴细胞亚群数据。结果在患者EGFR-TKI耐药前,患者接受EGFR-TKI单药治疗后外周血CD4+T淋巴细胞,CD8+T淋巴细胞,CD3+T淋巴细胞数量较接受EGFR-TKI单药治疗之前显著降低(P<0.05);患者接受EGFR-TKI联合胸腺肽α1治疗后外周血CD4+T淋巴细胞,CD8+T淋巴细胞,CD3+T淋巴细胞数量与EGFR-TKI单药治疗前相比稍降低,但无统计学差异(P> 0.05)。结论胸腺肽α1在某种程度上可以缓解EGFR-TKI对EGFR突变NSCLC患者外周血T淋巴细胞亚群的抑制。

Objective Comparative analysis of peripheral blood T lymphocyte subsets before patients treated with epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) and patients after receiving EGFR-TKI monotherapy or combined with Thymosin α1 therapy. Methods The data of peripheral blood T lymphocyte subsets of patients receiving EGFR-TKI and EGFR-TKI combined with Thymosin α1 was collected from May 2008 to August 2018. Results The number of Peripheral blood CD4^+, CD8^+ and CD3^+ T lymphocyte of patients were decreased after EGFR-TKI treatment alone( P <0.05), the number of those T lymphocytes shown no difference before EGFR-TKI monotherapy and after receiving EGFR-TKI plus Thymosin α1 therapy ( P >0.05). Conclusions EGFR-TKI could decrease the peripheral blood T lymphocyte subsets of patients treated with EGFR-TKI, thymosin α1 was able to reverse the inhibitory effect of EGFR-TKI on peripheral blood T lymphocyte subsets of patients to some extent.